| Literature DB >> 21404915 |
Chiara Benedetto1, Luca Marozio, Annalisa Tancredi, Elisa Picardo, Paola Nardolillo, Anna Maria Tavella, Loredana Salton.
Abstract
The HELLP syndrome is a serious complication of pregnancy characterized by hemolysis (H), elevated liver (EL) enzymes, and low platelet (LP) count that occurs in 0.2-0.6% of all pregnancies and in 10-20% of cases with severe preeclampsia and frequently leads to adverse maternal and perinatal outcome. The exact pathobiology of HELLP syndrome has not been clearly defined. As it is considered a form or a complication of severe preeclampsia, it likely has its origin in aberrant placental development and function resulting in ischemia-producing oxidative stress. However, there is still a debate on whether HELLP must be considered a severe form of preeclampsia or a separate disease entity. It can be described as a placenta-induced disease, as is preeclampsia itself, but with a more acute and predominant inflammatory process typically targeting the liver and with a greater activation of the coagulation system. This occurs during a disordered immunologic process and may be due to a genetic predisposition. In this review, we discuss the main biochemical characteristics of HELLP syndrome, particularly focusing on molecular aspects of placental involvement and maternal systemic responses.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21404915 DOI: 10.1016/b978-0-12-385855-9.00004-7
Source DB: PubMed Journal: Adv Clin Chem ISSN: 0065-2423 Impact factor: 5.394